Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 325 across all filing types
Latest filing 2026-06-09 Director's Dealing
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 93% confidence The document is a brief press release announcing notifications of share transactions by a member of the Executive Committee and Board of Directors. This clearly corresponds to insider trades by directors/executives, matching the “Director’s Dealing” category.
2026-06-09 English
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing a clinical trial milestone (first patient randomized in PREDICT-1). It does not contain financial statements, governance changes, earnings data, or proxy materials—nor is it announcing the release of a formal report. It is a general corporate announcement, so it falls under the fallback category for miscellaneous regulatory or disclosure announcements.
2026-06-09 English
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Investor Presentation Classification · 81% confidence The document is a press release announcing that company management will present at the 47th Annual Goldman Sachs Global Healthcare Conference, providing an overview of the business, strategic pipeline highlights, and webcast registration details. It is not an earnings release, regulatory filing, or formal report but rather an investor‐focused presentation event announcement. This aligns with the definition of an Investor Presentation (IP).
2026-06-08 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 98% confidence The document is a Globe Newswire announcement titled "Notifications of Transactions by Persons Discharging Managerial Responsibilities" which specifically relates to the vesting and settlement of RSUs previously granted to a director. This is a standard insider transaction disclosure by company directors or senior management. This clearly falls under the "Director's Dealing" category.
2026-05-29 English
Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki
Regulatory Filings Classification · 85% confidence The document is a corporate press release (GlobeNewswire) announcing topline results from Phase 3 clinical trials and discussing forward-looking statements, trial endpoints, and upcoming analyst/fiscal events. It does not contain financial earnings data, formal financial statements, or detailed regulatory filings; nor is it an Annual/Interim Report, earnings release, proxy statement, or investor presentation. It does not fit any specific category except the catch-all Regulatory Filings (RNS) for miscellaneous announcements. Therefore, the correct classification is RNS.
2026-05-29 Icelandic
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing topline clinical trial results for a Phase 3 program and inviting investors to a conference call. It does not contain actual financial statements (so it is not an Interim or Annual Report), nor is it an earnings release focused on quarterly financial performance. It is not a regulatory form or proxy, nor does it fit capital markets, governance, or M&A categories. This type of general corporate announcement that does not neatly fit a specific category falls under the fallback 'Regulatory Filings' (RNS).
2026-05-29 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.